Central Valley Advisors’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-5,250
Closed -$536K 162
2024
Q2
$536K Sell
5,250
-356
-6% -$11.9K 0.23% 67
2024
Q1
$200K Buy
+5,606
New +$194K 0.1% 157

Other funds holding SBIO

Central Valley Advisors's SBIO Position: Q3 2024 in Review

Central Valley Advisors sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q3 2024, closing a stake of 5,250 shares — an estimated $536K sold.

Central Valley Advisors first reported a position in SBIO in Q1 2024 and held it in 2 quarters. The position peaked at $536K in Q2 2024. 37 funds tracked by Wall St. Rank hold SBIO as of Q3 2024.

  • Central Valley Advisors reported no remaining ALPS Medical Breakthroughs ETF position as of Q3 2024 after selling out during the quarter.
  • Central Valley Advisors sold 5,250 ALPS Medical Breakthroughs ETF shares in Q3 2024, an estimated $536K.
  • Central Valley Advisors first reported a position in ALPS Medical Breakthroughs ETF in Q1 2024 and held it in 2 quarters.
  • Central Valley Advisors's ALPS Medical Breakthroughs ETF position peaked at $536K in Q2 2024.
  • 37 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2024.

Based on Central Valley Advisors's 13F filing for Q3 2024, filed 4 Oct 2024.